SCHEMBL6490065

SCHEMBL6490065

COP(=O)(CC(=O)c1ccc(C)c(Br)c1)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.51
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
TSHR P16473 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
MTOR P42345 5/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
DUSP3 P51452 1/20 0.40
PTPN5 P54829 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9548021 0.79 GSK3B (0.50) HPGDALDH1A1RAB9ANPC1MEN1
SCHEMBL3735121 0.79 PIM1 (0.47) ALDH1A1RAB9AMEN1KMT2ALMNA
SCHEMBL6490069 0.78 HPGD (0.51) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL10357072 0.77 LMNA (0.51) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL5733071 0.77 L3MBTL1 (0.49) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL20018287 0.75 HPGD (0.62) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL1232165 0.75 HPGD (0.57) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL29977001 0.75 HPGD (0.57) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL14105309 0.75 MAPT (0.56) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL5733603 0.74 PTPN1 (0.54) HPGDALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1863768-A Prostaglandin analogs as agonists of the EP4 receptor HOFFMANN LA ROCHE (CH) 2006-11-15 CN disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 HPGD 692/4885ALDH1A1 569/4885SMN1; SMN2 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.